{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:59:49Z","timestamp":1783033189931,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Veterans\u2019 Affairs Health Services Research and Development Service","award":["HX003655-01A2"],"award-info":[{"award-number":["HX003655-01A2"]}]},{"name":"Department of Veterans\u2019 Affairs Health Services Research and Development Service","award":["HX003655-01A2"],"award-info":[{"award-number":["HX003655-01A2"]}]},{"name":"Department of Veterans\u2019 Affairs Health Services Research and Development Service","award":["HX003655-01A2"],"award-info":[{"award-number":["HX003655-01A2"]}]},{"name":"Department of Veterans\u2019 Affairs Health Services Research and Development Service","award":["HX003655-01A2"],"award-info":[{"award-number":["HX003655-01A2"]}]},{"name":"Department of Veterans\u2019 Affairs Health Services Research and Development Service","award":["HX003655-01A2"],"award-info":[{"award-number":["HX003655-01A2"]}]},{"name":"Department of Veterans\u2019 Affairs Health Services Research and Development Service","award":["HX003655-01A2"],"award-info":[{"award-number":["HX003655-01A2"]}]},{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety","award":["# CIN 13-413"],"award-info":[{"award-number":["# CIN 13-413"]}]},{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety","award":["# CIN 13-413"],"award-info":[{"award-number":["# CIN 13-413"]}]},{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety","award":["# CIN 13-413"],"award-info":[{"award-number":["# CIN 13-413"]}]},{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety","award":["# CIN 13-413"],"award-info":[{"award-number":["# CIN 13-413"]}]},{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety","award":["# CIN 13-413"],"award-info":[{"award-number":["# CIN 13-413"]}]},{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety","award":["# CIN 13-413"],"award-info":[{"award-number":["# CIN 13-413"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Metabolic dysfunction associated steatotic liver disease (MASLD) is the most common chronic liver disorder in the world. Most patients with MASLD are undiagnosed, untreated and unreferred. Treatment depends on diagnosis and accurate staging of fibrosis risk, and therefore screening at the primary care setting coupled with consistent, timely, evidence-based, widely accessible, and testable management processes is critical. Randomized controlled trials of methods for screening, diagnosis, severity stratification, and referral are lacking. We previously validated the MASLD clinical care pathway (MCCP), a multistep algorithmic process geared to support primary care settings in screening, diagnosis, risk stratification, and suggested referral and treatment of patients with MASLD. We will evaluate the effectiveness of the MCCP intervention compared to usual care in improving MASLD care process and patient outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A two-arm, parallel, cluster-randomized trial will assess the effect of the MCCP intervention comprised of an e-trigger and structured provider education on screening, diagnosis, referral, and treatment for MASLD. Clusters are Veterans Affairs (VA) patient-centered primary care clinics, called Patient Aligned Care Teams (PACTs). This 4-year study will include three phases: (1) formative assessment to explore barriers to feasibility and acceptability of intervention among providers and patients and adapt MCCP for utilization by VA PACTs, (2) cluster-randomized trial to examine the effectiveness of the MCCP compared to usual care, and (3) summative evaluation to identify patient and provider characteristics associated with effectiveness of MCCP and plan for future implementation. The primary outcome will be a composite dichotomous variable for making a new MASLD diagnosis and completing severity risk stratification of MASLD. Secondary outcomes include referral and receipt of hepatology specialty care for patients with MASLD and advanced fibrosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Our randomized controlled trial will be the first to systematically implement the MCCP using strategies that are clinically relevant, adaptable and scalable. If successful, the MCCP will improve outcomes for patients with MASLD through early detection, accurate risk stratification, and timely treatment within primary care settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This trial has been registered on clinicaltrails.gov (# NCT06671886), registration date: 10\u201331-2024.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-12737-2","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:01:29Z","timestamp":1746500489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol"],"prefix":"10.1186","volume":"25","author":[{"given":"Kyler M.","family":"Godwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Grigoryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Thrift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traber","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himabindu","family":"Kadiyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zimolzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavish R.","family":"Patidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"5","key":"12737_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/hep.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605\u201316. https:\/\/doi.org\/10.1002\/hep.31173.","journal-title":"Hepatology"},{"issue":"5","key":"12737_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.32228","volume":"75","author":"JM Paik","year":"2022","unstructured":"Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204\u201317. https:\/\/doi.org\/10.1002\/hep.32228.","journal-title":"Hepatology"},{"issue":"5","key":"12737_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"7","key":"12737_CR4","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep4.1935","volume":"6","author":"M Noureddin","year":"2022","unstructured":"Noureddin M, Ntanios F, Malhotra D, et al. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017\u20132018 transient elastography data and application of machine learning. Hepatol Commun. 2022;6(7):1537\u201348. https:\/\/doi.org\/10.1002\/hep4.1935.","journal-title":"Hepatol Commun"},{"issue":"2","key":"12737_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","volume":"75","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2021.02.034.","journal-title":"J Hepatol"},{"issue":"5","key":"12737_CR6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cgh.2022.05.046","volume":"21","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Nguyen TH, Pham C, et al. The prevalence and determinants of NAFLD and MAFLD and their severity in the va primary care setting. Clin Gastroenterol Hepatol. 2023;21(5):1252-1260 e5. https:\/\/doi.org\/10.1016\/j.cgh.2022.05.046.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"12737_CR7","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1007\/s10620-024-08437-2","volume":"69","author":"AP Thrift","year":"2024","unstructured":"Thrift AP, Nguyen Wenker TH, Godwin K, et al. An electronic health record model for predicting risk of hepatic fibrosis in primary care patients. Dig Dis Sci. 2024;69(7):2430\u20136. https:\/\/doi.org\/10.1007\/s10620-024-08437-2.","journal-title":"Dig Dis Sci"},{"key":"12737_CR8","doi-asserted-by":"publisher","unstructured":"Heredia NI, Thrift AP, Ramsey DJ, Loomba R, El-Serag HB. Association of diet quality with metabolic (dysfunction) associated fatty liver disease in veterans in primary care. Nutrients. 2023;15(11).\u00a0https:\/\/doi.org\/10.3390\/nu15112598.","DOI":"10.3390\/nu15112598"},{"issue":"4","key":"12737_CR9","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10620-021-06955-x","volume":"67","author":"N Noureddin","year":"2022","unstructured":"Noureddin N, Noureddin M, Singh A, Alkhouri N. Progression of nonalcoholic fatty liver disease-associated fibrosis in a large cohort of patients with type 2 diabetes. Dig Dis Sci. 2022;67(4):1379\u201388. https:\/\/doi.org\/10.1007\/s10620-021-06955-x.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"12737_CR10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","volume":"21","author":"P Le","year":"2023","unstructured":"Le P, Payne JY, Zhang L, et al. Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol. 2023;21(5):1154\u201368. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"12737_CR11","doi-asserted-by":"publisher","unstructured":"Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5).\u00a0https:\/\/doi.org\/10.3390\/ijms17050774.","DOI":"10.3390\/ijms17050774"},{"issue":"7","key":"12737_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921\u201337. https:\/\/doi.org\/10.1007\/s00392-020-01709-7.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"12737_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","volume":"21","author":"CH Ng","year":"2023","unstructured":"Ng CH, Lim WH, Hui Lim GE, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(4):931-939 e5. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.014.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"12737_CR14","doi-asserted-by":"publisher","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2021;115. https:\/\/doi.org\/10.1016\/j.metabol.2020.154455.","journal-title":"Metabolism"},{"issue":"6","key":"12737_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"4","key":"12737_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"1","key":"12737_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ajg.2014.134","volume":"110","author":"P Blais","year":"2015","unstructured":"Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015;110(1):10\u20134. https:\/\/doi.org\/10.1038\/ajg.2014.134.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"12737_CR18","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","volume":"61","author":"P Blais","year":"2016","unstructured":"Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61(6):1714\u201320. https:\/\/doi.org\/10.1007\/s10620-015-4000-6.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"12737_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657\u201369. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.049.","journal-title":"Gastroenterology"},{"key":"12737_CR20","doi-asserted-by":"publisher","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;17(4):374\u2013444. https:\/\/doi.org\/10.1159\/000539371.","DOI":"10.1159\/000539371"},{"issue":"1","key":"12737_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.healthpol.2017.06.002","volume":"122","author":"FRM Leijten","year":"2018","unstructured":"Leijten FRM, Struckmann V, van Ginneken E, et al. The SELFIE framework for integrated care for multi-morbidity: development and description. Health Policy. 2018;122(1):12\u201322. https:\/\/doi.org\/10.1016\/j.healthpol.2017.06.002.","journal-title":"Health Policy"},{"issue":"2","key":"12737_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/bmjqs-2018-008086","volume":"28","author":"DR Murphy","year":"2019","unstructured":"Murphy DR, Meyer AN, Sittig DF, Meeks DW, Thomas EJ, Singh H. Application of electronic trigger tools to identify targets for improving diagnostic safety. BMJ Qual Saf. 2019;28(2):151\u20139. https:\/\/doi.org\/10.1136\/bmjqs-2018-008086.","journal-title":"BMJ Qual Saf"},{"key":"12737_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. https:\/\/doi.org\/10.1186\/1748-5908-4-50.","journal-title":"Implement Sci."},{"key":"12737_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, Harden SM, Gaglio B, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64. https:\/\/doi.org\/10.3389\/fpubh.2019.00064.","journal-title":"Front Public Health"},{"issue":"3","key":"12737_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1370\/afm.141","volume":"2","author":"S Killip","year":"2004","unstructured":"Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann Fam Med. 2004;2(3):204\u20138. https:\/\/doi.org\/10.1370\/afm.141.","journal-title":"Ann Fam Med"},{"key":"12737_CR26","doi-asserted-by":"publisher","first-page":"112516","DOI":"10.1016\/j.psychres.2019.112516","volume":"280","author":"AB Hamilton","year":"2019","unstructured":"Hamilton AB, Finley EP. Qualitative methods in implementation research: an introduction. Psychiatry Res. 2019;280. https:\/\/doi.org\/10.1016\/j.psychres.2019.112516.","journal-title":"Psychiatry Res"},{"issue":"9","key":"12737_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12737-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12737-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12737-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:01:30Z","timestamp":1746500490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12737-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12737"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12737-2","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Baylor College of Medicine (H- 53734). Participants in Aims 1 and 3 of the study are consented prior to their participation in individual interviews and focus groups. Recruitment is ongoing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"645"}}